Goldman Sachs
XBI icon

Goldman Sachs’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Goldman Sachs’s Portfolio XBI Stock Details XBI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.75B Sell
13,719,344
-6,177,074
-31% -$771M 0.2% 80
2025
Q4 		$2.43B Sell
19,896,418
-2,836,442
-12% -$325M 0.3% 44
2025
Q3 		$2.28B Buy
22,732,860
+4,636,025
+26% +$418M 0.28% 48
2025
Q2 		$1.5B Buy
18,096,835
+4,997,277
+38% +$399M 0.2% 76
2025
Q1 		$1.06B Buy
13,099,558
+3,544,529
+37% +$317M 0.17% 99
2024
Q4 		$861M Sell
9,555,029
-3,185,665
-25% -$309M 0.14% 128
2024
Q3 		$1.26B Buy
12,740,694
+789,077
+7% +$77.5M 0.2% 82
2024
Q2 		$1.11B Buy
11,951,617
+2,069,350
+21% +$186M 0.19% 89
2024
Q1 		$938M Sell
9,882,267
-279,842
-3% -$26M 0.17% 109
2023
Q4 		$907M Sell
10,162,109
-2,669,895
-21% -$198M 0.17% 104
2023
Q3 		$937M Buy
12,832,004
+2,523,251
+24% +$202M 0.2% 90
2023
Q2 		$858M Buy
10,308,753
+5,185,843
+101% +$434M 0.18% 93
2023
Q1 		$390M Buy
5,122,910
+12,685
+0.2% +$1.05M 0.09% 216
2022
Q4 		$424M Buy
5,110,225
+90,486
+2% +$7.33M 0.1% 193
2022
Q3 		$398M Sell
5,019,739
-1,578,160
-24% -$133M 0.1% 178
2022
Q2 		$490M Buy
6,597,899
+896,136
+16% +$67.3M 0.12% 129
2022
Q1 		$512M Sell
5,701,763
-2,381,440
-29% -$220M 0.11% 163
2021
Q4 		$905M Buy
8,083,203
+1,229,149
+18% +$148M 0.18% 86
2021
Q3 		$862M Buy
6,854,054
+804,759
+13% +$104M 0.18% 85
2021
Q2 		$819M Sell
6,049,295
-4,907,158
-45% -$645M 0.18% 89
2021
Q1 		$1.49B Sell
10,956,453
-5,135,573
-32% -$769M 0.37% 36
2020
Q4 		$2.27B Buy
16,092,026
+4,017,839
+33% +$515M 0.58% 21
2020
Q3 		$1.35B Sell
12,074,187
-4,034,230
-25% -$452M 0.38% 33
2020
Q2 		$1.8B Sell
16,108,417
-1,183,344
-7% -$117M 0.55% 20
2020
Q1 		$1.34B Buy
17,291,761
+6,656,476
+63% +$589M 0.47% 23
2019
Q4 		$1.01B Buy
10,635,285
+3,858,536
+57% +$334M 0.26% 69
2019
Q3 		$517M Buy
6,776,749
+245,133
+4% +$20.4M 0.15% 118
2019
Q2 		$573M Sell
6,531,616
-1,874,359
-22% -$160M 0.16% 105
2019
Q1 		$761M Buy
8,405,975
+1,702,845
+25% +$145M 0.23% 72
2018
Q4 		$481M Sell
6,703,130
-2,235,877
-25% -$180M 0.15% 104
2018
Q3 		$857M Buy
8,939,007
+454,472
+5% +$44.1M 0.22% 71
2018
Q2 		$808M Buy
8,484,535
+1,031,009
+14% +$94.8M 0.22% 68
2018
Q1 		$654M Buy
7,453,526
+1,778,312
+31% +$162M 0.17% 101
2017
Q4 		$482M Buy
5,675,214
+127,506
+2% +$10.7M 0.12% 171
2017
Q3 		$480M Sell
5,547,708
-544,698
-9% -$43.7M 0.12% 146
2017
Q2 		$470M Buy
6,092,406
+384,729
+7% +$27.3M 0.12% 146
2017
Q1 		$396M Buy
5,707,677
+726,191
+15% +$48.8M 0.11% 162
2016
Q4 		$295M Sell
4,981,486
-4,177,682
-46% -$258M 0.08% 232
2016
Q3 		$607M Buy
9,159,168
+1,257,170
+16% +$77.8M 0.18% 77
2016
Q2 		$427M Sell
7,901,998
-3,541,330
-31% -$194M 0.14% 117
2016
Q1 		$591M Buy
11,443,328
+2,324,677
+25% +$121M 0.19% 81
2015
Q4 		$640M Sell
9,118,651
-5,733,995
-39% -$391M 0.2% 80
2015
Q3 		$925M Buy
14,852,646
+1,755,477
+13% +$138M 0.31% 38
2015
Q2 		$1.1B Buy
13,097,169
+2,262,723
+21% +$176M 0.34% 33
2015
Q1 		$814M Buy
10,834,446
+961,893
+10% +$67.2M 0.26% 51
2014
Q4 		$614M Sell
9,872,553
-262,155
-3% -$14.9M 0.19% 81
2014
Q3 		$527M Buy
10,134,708
+1,962,768
+24% +$100M 0.17% 100
2014
Q2 		$419M Buy
8,171,940
+2,141,649
+36% +$96.6M 0.13% 142
2014
Q1 		$286M Buy
6,030,291
+1,253,238
+26% +$64.2M 0.09% 216
2013
Q4 		$207M Buy
4,777,053
+1,715,610
+56% +$71M 0.07% 323
2013
Q3 		$132M Sell
3,061,443
-110,478
-3% -$4.48M 0.05% 462
2013
Q2 		$110M Buy
+3,171,921
New +$111M 0.04% 515

Other funds holding XBI

BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
JFG
Jefferies Financial Group New York $14.6B AUM 40.95% 1-Year Est. Return

Goldman Sachs's XBI Position: Q1 2026 in Review

Goldman Sachs reduced its State Street SPDR S&P Biotech ETF (XBI) stake by 31% in Q1 2026, selling an estimated $771M and leaving 13,719,344 shares worth $1.75B. The position accounts for 0.2% of the portfolio, ranked #80.

Goldman Sachs first reported a position in XBI in Q2 2013 and has held it in 52 quarters since. The position peaked at $2.43B in Q4 2025. 813 funds tracked by Wall St. Rank hold XBI as of Q1 2026.

  • Goldman Sachs held 13,719,344 shares of State Street SPDR S&P Biotech ETF worth $1.75B as of Q1 2026.
  • Goldman Sachs sold 6,177,074 State Street SPDR S&P Biotech ETF shares in Q1 2026, an estimated $771M.
  • State Street SPDR S&P Biotech ETF made up 0.2% of Goldman Sachs's portfolio in Q1 2026, its #80 holding.
  • Goldman Sachs first reported a position in State Street SPDR S&P Biotech ETF in Q2 2013 and has held it in 52 quarters since.
  • Goldman Sachs's State Street SPDR S&P Biotech ETF position peaked at $2.43B in Q4 2025.
  • 813 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.